激动剂-话题@MedSci

#激动剂#

173篇内容 | 3318人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1627866, encodeId=fd64162e866d0, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Cell Death Dis：AMPK激动剂通过激活高脂和链脲佐菌素诱导的糖尿病小鼠的自噬来缓解肾小管间质纤维化。, objectType=article, longId=218751, objectId=0dac218e51e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dac218e51e5, replyNumber=0, likeNumber=75, createdTime=2021-10-18, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dac218e51e5, moduleTitle=Cell Death Dis：AMPK激动剂通过激活高脂和链脲佐菌素诱导的糖尿病小鼠的自噬来缓解肾小管间质纤维化。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dac218e51e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627865, encodeId=e133162e86539, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Thorax：急性哮喘成人或儿童患者肾上腺素与选择性β-2激动剂的疗效比较, objectType=article, longId=218301, objectId=f9cf21830177, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9cf21830177, replyNumber=0, likeNumber=62, createdTime=2021-10-11, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9cf21830177, moduleTitle=Thorax：急性哮喘成人或儿童患者肾上腺素与选择性β-2激动剂的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9cf21830177)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627864, encodeId=b56e162e8643c, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Eur Respir J：短效β2激动剂处方与哮喘不良临床结局相关, objectType=article, longId=217940, objectId=93d921e940d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93d921e940d9, replyNumber=0, likeNumber=61, createdTime=2021-10-01, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93d921e940d9, moduleTitle=Eur Respir J：短效β2激动剂处方与哮喘不良临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93d921e940d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627863, encodeId=c6af162e863a3, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, objectType=article, longId=217820, objectId=f24821e820ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24821e820ef, replyNumber=0, likeNumber=69, createdTime=2021-09-30, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24821e820ef, moduleTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24821e820ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627862, encodeId=b24b162e862b9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Toll样受体激动剂治疗COVID-19，II期试验显示积极的顶线结果, objectType=article, longId=217660, objectId=dc4e21e66017, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc4e21e66017, replyNumber=0, likeNumber=86, createdTime=2021-09-27, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc4e21e66017, moduleTitle=Toll样受体激动剂治疗COVID-19，II期试验显示积极的顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc4e21e66017)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627861, encodeId=4906162e86179, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes Care：胰高血糖素样肽1受体激动剂与糖尿病性视网膜病变发生风险的关系, objectType=article, longId=216622, objectId=130b2166226e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=130b2166226e, replyNumber=0, likeNumber=64, createdTime=2021-09-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=130b2166226e, moduleTitle=Diabetes Care：胰高血糖素样肽1受体激动剂与糖尿病性视网膜病变发生风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=130b2166226e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627860, encodeId=5219162e860a5, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Blood：血小板生成素受体激动剂在ITP老年患者中的实际应用情况, objectType=article, longId=216350, objectId=6bdb21635063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bdb21635063, replyNumber=0, likeNumber=71, createdTime=2021-08-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bdb21635063, moduleTitle=Blood：血小板生成素受体激动剂在ITP老年患者中的实际应用情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bdb21635063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627859, encodeId=3288162e8594c, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, objectType=article, longId=216263, objectId=a32e21626362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a32e21626362, replyNumber=0, likeNumber=115, createdTime=2021-08-26, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a32e21626362, moduleTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a32e21626362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627858, encodeId=fca0162e858f6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, objectType=article, longId=213906, objectId=58312139068b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58312139068b, replyNumber=0, likeNumber=78, createdTime=2021-07-09, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58312139068b, moduleTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58312139068b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627857, encodeId=d779162e8573b, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, objectType=article, longId=213591, objectId=78a9213591c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a9213591c8, replyNumber=0, likeNumber=71, createdTime=2021-07-02, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a9213591c8, moduleTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78a9213591c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627856, encodeId=2c1e162e856b6, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, objectType=article, longId=213289, objectId=5cdb21328936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cdb21328936, replyNumber=0, likeNumber=75, createdTime=2021-06-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cdb21328936, moduleTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cdb21328936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627855, encodeId=8996162e8552f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果, objectType=article, longId=212351, objectId=4525212351b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4525212351b7, replyNumber=0, likeNumber=98, createdTime=2021-06-08, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4525212351b7, moduleTitle=礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4525212351b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627854, encodeId=c04a162e85453, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JAMA：α2-肾上腺素受体激动剂 vs 神经兴奋类药物治疗学龄前儿童注意力缺陷/多动障碍, objectType=article, longId=211153, objectId=bb1a21115304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb1a21115304, replyNumber=0, likeNumber=80, createdTime=2021-05-13, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb1a21115304, moduleTitle=JAMA：α2-肾上腺素受体激动剂 vs 神经兴奋类药物治疗学龄前儿童注意力缺陷/多动障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb1a21115304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627853, encodeId=bc2a162e85327, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=AP&T: 5-HT 4受体激动剂对胃轻瘫患者肠道蠕动恢复的影响, objectType=article, longId=210263, objectId=bea6210263e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bea6210263e7, replyNumber=0, likeNumber=55, createdTime=2021-04-23, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bea6210263e7, moduleTitle=AP&T: 5-HT 4受体激动剂对胃轻瘫患者肠道蠕动恢复的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bea6210263e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627852, encodeId=5b5e162e852d3, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetes Obes Metab：双胰高血糖素样肽-1/胰高血糖素受体激动剂SAR425899可明显改善T2D患者的餐后糖代谢, objectType=article, longId=209702, objectId=ff5f209e02a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff5f209e02a5, replyNumber=0, likeNumber=71, createdTime=2021-04-10, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff5f209e02a5, moduleTitle=Diabetes Obes Metab：双胰高血糖素样肽-1/胰高血糖素受体激动剂SAR425899可明显改善T2D患者的餐后糖代谢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff5f209e02a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627851, encodeId=295c162e85141, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Clin Gastroenterology H: 5-HT-4受体激动剂米沙必利治疗肠易激综合征患者的疗效和安全性分析, objectType=article, longId=207743, objectId=d89920e7436b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89920e7436b, replyNumber=0, likeNumber=77, createdTime=2021-03-01, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89920e7436b, moduleTitle=Clin Gastroenterology H: 5-HT-4受体激动剂米沙必利治疗肠易激综合征患者的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89920e7436b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627850, encodeId=6e72162e850c9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Nature BME：多价STING激动剂对天然免疫通路的长效激活, objectType=article, longId=207557, objectId=0a7320e557f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7320e557f6, replyNumber=0, likeNumber=83, createdTime=2021-02-26, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7320e557f6, moduleTitle=Nature BME：多价STING激动剂对天然免疫通路的长效激活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7320e557f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627849, encodeId=273e162e8490e, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）, objectType=article, longId=207193, objectId=f13120e19316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f13120e19316, replyNumber=0, likeNumber=88, createdTime=2021-02-18, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f13120e19316, moduleTitle=ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f13120e19316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627848, encodeId=073b162e848c1, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, objectType=article, longId=205766, objectId=c84a205e66fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a205e66fd, replyNumber=0, likeNumber=35, createdTime=2021-01-17, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a205e66fd, moduleTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a205e66fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627847, encodeId=cf5e162e8477f, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=JCI: Kisspeptin受体激动剂对女性生殖系统疾病具有治疗潜力, objectType=article, longId=205671, objectId=f8832056e1eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8832056e1eb, replyNumber=0, likeNumber=79, createdTime=2021-01-14, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8832056e1eb, moduleTitle=JCI: Kisspeptin受体激动剂对女性生殖系统疾病具有治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8832056e1eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激动剂

2020-05-29

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Cell Death Dis：AMPK激动剂通过激活高脂和链脲佐菌素诱导的糖尿病小鼠的自噬来缓解肾小管间质纤维化。

2021-10-18

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Thorax：急性哮喘成人或儿童患者肾上腺素与选择性β-2激动剂的疗效比较

2021-10-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Eur Respir J：短效β2激动剂处方与哮喘不良临床结局相关

2021-10-01

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益

2021-09-30

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Toll样受体激动剂治疗COVID-19，II期试验显示积极的顶线结果

2021-09-27

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes Care：胰高血糖素样肽1受体激动剂与糖尿病性视网膜病变发生风险的关系

2021-09-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Blood：血小板生成素受体激动剂在ITP老年患者中的实际应用情况

2021-08-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率

2021-08-26

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平

2021-07-09

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用

2021-07-02

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响

2021-06-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果

2021-06-08

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JAMA：α2-肾上腺素受体激动剂 vs 神经兴奋类药物治疗学龄前儿童注意力缺陷/多动障碍

2021-05-13

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

AP&T: 5-HT 4受体激动剂对胃轻瘫患者肠道蠕动恢复的影响

2021-04-23

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetes Obes Metab：双胰高血糖素样肽-1/胰高血糖素受体激动剂SAR425899可明显改善T2D患者的餐后糖代谢

2021-04-10

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Clin Gastroenterology H: 5-HT-4受体激动剂米沙必利治疗肠易激综合征患者的疗效和安全性分析

2021-03-01

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Nature BME：多价STING激动剂对天然免疫通路的长效激活

2021-02-26

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）

2021-02-18

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势

2021-01-17

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

JCI: Kisspeptin受体激动剂对女性生殖系统疾病具有治疗潜力

2021-01-14

科室
- - 订阅+
  - 更多科室
工具
服务